Current Trial| Volume 4, ISSUE 3, P212-217, August 2003

Phase I/II Study of Treatment of Stage IV Breast Cancer with OKT3 x Trastuzumab—Armed Activated T Cells

      This paper is only available as a PDF. To read, Please Download here.

      Key words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Clinical Breast Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Paterson AH
        • Lees AW
        • Hanson J
        • et al.
        Impact of chemotherapy of survival in metastatic breast cancer.
        Lancet. 1980; 2: 312
        • Fey MF
        • Brunner KW
        • Sonntag RW
        Prognostic factors in metastatic breast cancer.
        Cancer Clin Trials. 1981; 4: 237-247
        • Lum L
        Immunotherapy with activated T cells after high dose chemotherapy and PBSCT for breast cancer.
        in: Dicke K Keating A Autologous Blood and Marrow Transplantation. Carden Jennings, Charlottesville, VA2000: 95-110
        • Sen M
        • Wankowski DM
        • Garlie NK
        • et al.
        Use of anti-CD3 x anti- HER2/neu bispecific antibody for redirecting cytotoxicity of activated T cells toward HER2/neu+ tumors.
        J Hematother Stem Cell Res. 2001; 10: 247-260
        • Grabert RC
        • Smith J
        • Tiggs J
        • et al.
        Anti-CD3 activated T with OKT3 x herceptin bispecific antibody, survive and divide, and secrete cytokines and chemokines after multiple cycles of killing directed at Her2/neu+ tumor targets.
        American Association for Cancer Research. 2003; : 656
        • Smith J
        • Davol P
        • Kouttab N
        • et al.
        Anti-CD3 x anti-HER2/neu armed T cells inhibit tumor development or induced remissions in prostrate cancer bearing beige/SCID mice.
        Exp Hematol. 2002; 30 (Abstract #159).: 76
        • Lum LG
        • Rathore R
        • Colvin GA
        • et al.
        Targeting HER2/neu tumor cells with anti-CD3 activated T cells: clinical trials and trafficking studies.
        Proc Am Soc Clin Oncol. 2003; 23 (Abstract #719).: 179
        • Eshhar Z
        • Waks T
        • Gross G
        • et al.
        Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors.
        Proc Natl Acad Sci U S A. 1993; 90: 720-724
        • Eshhar Z
        • Waks T
        • Bendavid A
        • et al.
        Functional expression of chimeric receptor genes in human T cells.
        J Immunol Methods. 2001; 248: 67-76
        • Fields RC
        • Shimizu K
        • Mule JJ
        Murine dendritic cells pulsed with whole tumor lysates mediate potent antitumor immune responses in vitro and in vivo.
        Proc Natl Acad Sci U S A. 1998; 95: 9482-9487
        • Casares S
        • Inaba K
        • Brumeanu TD
        • et al.
        Antigen presentation by dendritic cells after immunization with DNA encoding a major histocompatibility complex class II-restricted viral epitope.
        J Exp Med. 1997; 186: 1481-1486
        • Ashley DM
        • Faiola B
        • Nair S
        • et al.
        Bone marrow-generated dendritic cells pulsed with tumor extracts or tumor RNA induce antitumor immunity against central nervous system tumors.
        J Exp Med. 1997; 186: 1177-1182
        • Boczkowski D
        • Nair SK
        • Snyder D
        • et al.
        Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo.
        J Exp Med. 1996; 184: 465-472
        • Tjandrawan T
        • Martin DM
        • Maeurer MJ
        • et al.
        Autologous human dendriphages pulsed with synthetic or natural tumor peptides elicit tumor-specific CTLs in vitro.
        J Immunother. 1998; 21: 149-157
        • Porgador A
        • Gilboa E
        Bone marrow-generated dendritic cells pulsed with a class I-restricted peptide are potent inducers of cytotoxic T lymphocytes.
        J Exp Med. 1995; 182: 255-260